PRESTIGE-AF

PREVENTION OF STROKE IN INTRACEREBRAL HAEMORRHAGE SURVIVORS WITH ATRIAL FIBRILLATION

Pharmacology Substudy

Personal Legal Representative Information Sheet and Consent Form

Chief Investigator: Prof Roland Veltkamp

WE INVITE YOU TO CONSIDER A SUBSTUDY OF PRESTIGE-AF

We are conducting a research study on the best stroke prevention for patients with atrial fibrillation (AF) who have recently had a bleed in their brain, also called an "intracerebral haemorrhage" (ICH).

You are being asked to consider this substudy on behalf of a patient, who is your relative, partner or close friend, because they are unable to make the decision for themselves.

- You are free to decide if you wish to make this decision or not.
- You are being asked to consider what the patient would want and should set aside your own personal views when making this decision.
- Before you decide whether to enrol the patient into the study , it is important for you to understand why the research is being done and what it will involve.
- Please take time to read the following information carefully. Discuss it with the patient if this is appropriate and with other relatives or friends.
- You are free to decide whether the patient should take part in this trial. If you choose for the patient not to take part, this will not affect the care they get from their doctors or their participation in the main PRESTIGE-AF Study.
- If you do decide for the patient to take part, you can withdraw them from the trial at any time without them being disadvantaged and without giving a reason.

- If in the future, the patient regains capacity to make their own decisions, they will be given all of the information and asked to decide if they want to take part or not. They will be free to withdraw from the trial and can do so without disadvantage.
- Ask us if there is anything that is not clear or if you would like more information.

BACKGROUND

In general, the requirement for a successful medication treatment is that the medicine is taken as prescribed and that the appropriate amount of medication reaches the patient.

However, it is sometimes difficult to adhere to a medication treatment plan. Moreover, other factors can influence the amount of medication that is absorbed into your body, including other medicines that the patient is taking, and other conditions that they may have. These complications can change their exposure to the medication and affect both the safety of the treatment and how effective it is.

We aim to find out if these issues are relevant to patients who are taking a DOAC. We equally plan to evaluate if patients succeed in regularly taking their DOAC and if their individual medication exposure is what we would expect it to be.

WHAT IS INVOLVED?

Your relative, partner or close friend is a participant in the PRESTIGE-AF Study and they are one of the 327 patients receiving a DOAC in the Study. DOAC medication exposure can be calculated by analysing the drug level in their blood at different time points before and after they take their DOAC within a dosing interval. To collect blood easily, we will use the dried blood spot (DBS) technique. This technique is advantageous because it only needs less than 4 drops of blood for an

accurate analysis. DBS is sampled by dripping blood on a special card. These cards will then be posted to the study laboratory for analysis.

The substudy is split into two parts, the patient can take part in one or both parts of the study.

PART 1

In part 1, the patient's blood will be collected during their follow-up visits for the main PRESTIGE-AF Study. A blood spot is taken from the needle when their safety blood sample is collected so no additional blood draw is required. There are no additional procedures for the patient if they are enrolled in part 1 of the substudy but we will be able to do more research.

PART 2

To calculate the patient's individual DOAC exposure, they can take part in a more detailed version of this study (part 2). The patient (or a caregiver) will be asked to collect additional blood drops on a DBS paper after each scheduled visit, i.e. at home. These will be taken from the tiny blood vessels (capillaries) in your fingertip. A trained healthcare practitioner will teach them (or a caregiver) how to perform and document this capillary blood sampling on their own (see Figure 1). A short video will be shown to them, and they will be shown how to access this to watch it again at home if they wish (www.prestige-af.org). The first of four blood samples will be collected at the centre under the supervision of the practitioner. Afterwards, the patient (or their caregiver) will collect three additional blood spots at home. The second spot should be generated the following morning, directly before they take their next DOAC. A third spot should be taken two hours after their DOAC intake and a fourth one eight hours after (see Figure 2). Then the DBS card needs to be left to dry before it is posted back to us in the provided postage-paid envelope.

The patient (or their caregiver) will also be asked to answer a few questions concerning other medicines they might be taking as well as

possible handling difficulties and to monitor their adherence on a visual scale.



Figure 1 Capillary blood sampling to create and mail a DBS



Figure 2 Time course of capillary blood sampling

POTENTIAL BENEFIT OF THIS SUBSTUDY

Participating in this substudy does not provide direct benefit for the patient. However, their data will help to reveal the potential pitfalls of a DOAC treatment. We will be able to see whether patients, in general, succeed in taking a DOAC and whether DOAC medication levels in the blood are as expected. The laboratory results will be used for scientific analysis and will not be reported back to the patient or their doctors. This is because the medication levels in their blood only have meaning in comparison with other patients' data and these are confidential and only available at the end of the study.

POTENTIAL RISK OF THIS SUBSTUDY

Having a blood sample taken is a low risk procedure and the the risks of sampling DBS are considered minimal. In the first part of this substudy there is no additional sample taken as the blood will be taken from the remaining blood left in the tubing after the patient's blood sample, therefore there is no additional risk to you.

In the second part, repetitive capillary blood sampling will be performed by the patient or their caregiver at home. In theory, local infections at the puncture site are possible but because single-use lancets (the instrument used to pinprick the finger) will be used and disinfectant swabs will be provided, the risk should be small. To minimise any risk, training will be provided in performing the procedure at each visit. The puncture site may slightly hurt, but the pain will ease after a few hours.

PARTICIPANT TIMELINE

The timeline is the same as the timeline of the main PRESTIGE-AF Study and substudy procedures will take place at your normal follow-up visits. If the patient participates in part 2 of the substudy, blood sampling for DBS will also include the day after your visits.

WHAT IF SOMETHING GOES WRONG?

Imperial College London holds insurance policies which apply to this study. If the patient experiences harm or injury as a result of taking part in this study, they will be eligible to claim compensation without having to prove that Imperial College is at fault. This does not affect their legal rights to seek compensation.

If they are harmed due to someone's negligence, then they may have grounds for a legal action. Regardless of this, if you or they wish to complain, or have any concerns about any aspect of the way the patient has been treated during the course of this study then the investigator should immediately be informed *(prestige-af@imperial.ac.uk)* The normal National Health Service mechanisms are also available to you and the patient. If you or the patient are still

not satisfied with the response, you may contact the Imperial College, Research Governance and Integrity Team.

HOW WILL WE USE INFORMATION ABOUT YOU

Imperial College London is the sponsor for this study and will act as the data controller for this study. This means that we are responsible for looking after the patient's information and using it properly. Imperial College London will keep their personal data for:

- 15 years after the study has finished in relation to data subject consent forms
- 15 years after the study has completed in relation to primary research data.

We will need to use information from the patient, their medical records, their GP or other healthcare providers for this research project.

This information will include:

- The patient's name
- Their contact details
- Their NHS Number
- Health information

People will use this information to do the research or to check the patient's records to make sure that the research is being done properly.

People who do not need to know who the patient is will not be able to see their name or contact details. Their data will have a code number instead.

We will keep all information about the patient safe and secure.

Some of their information will be sent to countries in the European Union. They must follow our rules about keeping the patient's information safe.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that the patient took part in the study.

LEGAL BASIS

As a university we use personally-identifiable information to conduct research to improve health, care and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when we use personally-identifiable information from people who have agreed to take part in research. This means that when you agree for the patient to take part in a research study, we will use their data in the ways needed to conduct and analyse the research study.

Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the interests of society as a whole. We do this by following the UK Policy Framework for Health and Social Care Research.

INTERNATIONAL TRANSFERS

There may be a requirement to transfer information to countries outside the European Economic Area (for example, to a research partner). Where this information contains the patient's personal data, Imperial College London will ensure that it is transferred in accordance with data protection legislation. If the data is transferred to a country which is not subject to a European Commission (EC) adequacy decision in respect of its data protection standards, Imperial College London will enter into a data sharing agreement with the recipient organisation that incorporates EC approved standard contractual clauses that safeguard how the patient's personal data is processed.

SHARING YOUR INFORMATION WITH OTHERS

For the purposes referred to in this privacy notice and relying on the bases for processing as set out above, we will share the patient's personal data with certain third parties.

- Other College employees, agents, contractors and service providers (for example, suppliers of printing and mailing services, email communication services or web services, or suppliers who help us carry out any of the activities described above). Our third party service providers are required to enter into data processing agreements with us. We only permit them to process the patient's personal data for specified purposes and in accordance with our policies.

- This clinical trial is part of a large European Union funded project. We are working with the following research collaborators across Europe who are all specialists in different fields. In order to answer the questions of our research we are all working together and therefore the patient's data will be shared with:

    - University Hospital Würzburg, Germany
    - Julius-Maximilans Universitaet Würzburg, Germany
    - Medizinische Universitaet Graz, Austria
    - Kings College London, UK
    - Fundacio Hospital Universitari Vall d'Hebron- Institut de Recerca, Spain
    - Universite de Bordeaux, France
    - Azienda Ospedaliera di Perugia, Italy
    - Region Nordjylland (North Denmark Region) , Denmark
    - Stroke Alliance for Europe, Belgium
    - Heidelberg University Hospital, Germany
    - University of Liverpool, UK

If you would like to find out more about the PRESTIGE-AF Project and what each partner does there is more information on our website www.prestige-af.org

WHAT ARE YOUR CHOICES ABOUT HOW YOUR INFORMATION IS USED

The patient can stop being part of the study at any time, without giving a reason, but we will keep information about them that we already have.

- We need to manage their records in specific ways for the research to be reliable. This means that we won't be able to let you or the patient see or change the data we hold about them.

- If you agree to the patient take part in this study, you will have the option for them to take part in future research using their data saved from this study.

WHERE CAN YOU FIND OUT MORE ABOUT HOW YOUR INFORMATION IS USED

You can find out more about how we use the patient's information

- at www.hra.nhs.uk/information-about-patients/
- by asking one of the research team
- by sending an email to hello@prestige-af.org
- www.prestige-af.org/privacy-cookie-policy/

COMPLAINTS

If you, or the patient, wish to raise a complaint on how we have handled their personal data, please contact Imperial College London's Data Protection Officer via:

- email at dpo@imperial.ac.uk
- telephone on 020 7594 3502 and/or
- via post at Imperial College London, Data Protection Officer, Faculty Building Level 4, London SW7 2AZ.

If you, or the patient, are not satisfied with our response or believe we are processing their personal data in a way that is not lawful you or the patient, can complain to the Information Commissioner's Office

(ICO). The ICO does recommend that you seek to resolve matters with the data controller (us) first before involving the regulator.

FUNDER

A group of international researchers formed the PRESTIGE AF consortium, which applied for research funding. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754517.

ETHICAL REVIEW

This research was designed and reviewed by a consortium of experts within the field. There are several monitoring boards in place that will continue to review the trial throughout, to ensure the safety of participants.

This research has been reviewed and approved by the London Surrey Borders Research Ethics Committee and the Medicines and Healthcare Products Regulatory Agency. The Health Research Authority has approved this research to be conducted within the UK National Health Service.

FURTHER INFORMATION

It is important that you have enough information to decide whether to take part. If you have any questions, please contact the study team: *prestige-af@imperial.ac.uk*

Thank you for taking the time to read this information.

CONSENT FORM

Principal Investigator:

Participant ID:

	Please initial box
I confirm that I have read this information sheet and I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.	☐
I understand that I am giving this consent based on what I believe would be my relative/friend/partner's wishes. In my opinion they would be willing to participate.	☐
I understand that participation is voluntary and I or the person I am consenting for are free to withdraw at any time, without giving any reason, without medical care or legal rights being affected.	☐
I understand that sections of any of my relative/friend/partner's medical notes may be looked at by responsible individuals from NHS or from regulatory authorities where it is relevant to my taking part in this research.	☐
I give permission for these individuals to access my relative/friend/partner's records that are relevant to this research.	☐
I agree to my relative/friend/partner taking part in the whole substudy / part 1 only / part 2 only *(delete as applicable).*	☐

I agree that my relative/friend/partner's consent will override my consent when they are able to give informed consent. ☐

I give/do not give *(delete as applicable)* consent for remaining blood samples and information collected about my relative/friend/partner to be used to support other research in the future, including those outside of the EEA. ☐

_____

Name of Participant

_____	_____	_____
Name of Investigator taking consent	Date	Signature

_____	_____	_____
Name of legal Representative	Date	Signature

When completed: 1 for Participant, 1 for investigator site file, 1 to be kept in medical notes